HaitiDocs

Données / Portefeuille des partenaires / Royaume-Uni / Department for Business, Energy & Industrial Strategy

Cadre de modélisation mathématique pour l’estimation de la charge de la tuberculose

Titre publié : A mathematical modeling framework for tuberculosis burden estimation and economic evaluation of pharmaceutical interventions

Millions de dollars US sauf indication contraire. Exercice fiscal haïtien, d’octobre à septembre. L’exercice FY2026-27 a commencé le 1er octobre 2026.

Description

Tuberculosis (TB) is a major cause of disease and death globally. In 2015, WHO estimated there were 9.6 million TB cases and 1.5 TB deaths. Nearly 500,000 of these cases were resistant to two or more of the main drugs used to treat TB. New drugs, and combinations of drugs, are being developed to treat tuberculosis, as are new vaccines that may protect against disease in adults. Quantifying the burden of TB is fundamental to understanding its global epidemiology and for making appropriate resource allocation decisions. Most estimates of new TB case numbers each year rely strongly on the number of cases reported by countries in that year to WHO. Unfortunately, one in three TB cases are thought to go

suite

either undetected or unreported, so the number of cases reported underestimates the number of new cases. While one can correct for this, it is hard to know exactly how much to adjust the reported numbers. Some countries have good systems for recording causes of deaths, which can be used to estimate the number of deaths caused by TB. Increasingly, large and expensive prevalence surveys are being used to estimate the number of people with active disease in a population. These estimates are less subject to bias, but measure a different quantity. Little work has explored the best way of combining these three data sources. A major goal of this work is to use mathematical transmission models for burden estimation and provide a unified framework for all data. These models yield the number of new cases, deaths, and also the prevalence of disease. They explicitly represent disease transmission and so introduce a dependence between the number of new cases in different years. These models involve parameters evidenced from previous epidemiological work, but must be calibrated to learn from data on TB reports, deaths and prevalence. Calibration means adjusting imperfectly known model parameters in order to match observed model outputs to the data. This process provides a model that may be used to make predictions about burden, but may also teach us something about the underlying processes. Many of the parameters concerning the epidemiology and disease course of TB are quite uncertain, and this uncertainty is rarely represented fully in models needing calibration, but will be done in this project using statistical techniques that also allow comparison of different models' performance. TB burden estimation and calibration of transmission models are almost always carried out on a country-by-country basis. Many parameters describing disease progression are likely to be similar in different countries, even if their exact values differ for unknown reasons. Hierarchical modelling techniques allow such parameters to be correlated between countries. This can improve precision, particularly for countries with little data, as estimates can be informed by data from neighbouring countries. I will explore these techniques for the transmission model, and also in statistical modelling aiming to account for the observed patterns of drug-resistance. The transmission model will ultimately be extended to include different types of drug resistance. As new treatments and vaccines emerge, those with responsibility for public health will want to understand the potential impact these new technologies can have in terms of gains in health, and changes in spending. Producing cost-effectiveness and budget impact evidence requires a model that includes transmission, in order to account for indirect benefits accrued by avoiding secondary cases. We will use our model to provide guidance to decision-makers seeking to maximise health gain with limited resources. We will also analyse sources of uncertainty in the model to identify future research that would have most value in increasing the precision of burden estimates and in reducing decision uncertainty around the introduction of new interventions.

Partenaire
United Kingdom, Department for Business, Energy & Industrial Strategy
Secteur
Santé
Stade
Clôturée depuis le 31 août 2022
Début
1er septembre 2017
Clôture
31 août 2022
Part d’Haïti
1 % d’un financement multipays de 0,6
Entrée en vigueur
Non publié
Dernière transaction
31 mars 2021
Identifiant IATI
GB-GOV-13-FUND--GCRF-MR_P022081_1
Cycle de vie4 stades, 7 dates

Historique des stades

StadeDepuis le
Approuvée1er juillet 2017
En cours1er septembre 2017
En clôture30 juin 2022
Clôturée31 août 2022

Événements datés

ÉvénementDateSource
Premier engagement1er juillet 2017Écritures
Début prévu1er juillet 2017IATI
Début effectif1er septembre 2017IATI
Premier décaissement31 décembre 2017Écritures
Dernier décaissement31 mars 2021Écritures
Date de clôture30 juin 2022IATI
Fin effective31 août 2022IATI

Financement

Tableau 1.Position à la date des données par source (stocks), millions de dollars US

Cette pageMillions de dollars USSource
Engagement<0,1IATI
Décaissé<0,1IATI
Non décaisséNon publié
Coût totalNon publié

Montants IATI. Approuvé: Les engagements que le partenaire publie, convertis en $ É.-U. Décaissé à ce jour: Les décaissements (transaction IATI de type 3, fonds versés à une autre organisation) et les dépenses (type 4, fonds que l’éditeur dépense lui-même) que le partenaire publie, convertis en $ É.-U. Non décaissé: Le solde non décaissé que donne la fiche, quand le partenaire en publie un, en $ É.-U. Les montants selon la source

Modifications de l'opérationnon publié
Date de clôture initiale
Non publié
Prorogations de la date de clôture
Non publié
Restructurations
Non publié
Composante d'urgence
Non publié

Nouveaux engagements et décaissements par exercice

Décaissements, millions de dollars US
FY2016-17, non publién.p.16-17FY2017-18, <0,1 millions de dollars US<0,117-18FY2018-19, <0,1 millions de dollars US<0,118-19FY2019-20, <0,1 millions de dollars US<0,119-20FY2020-21, <0,1 millions de dollars US<0,120-21FY2016-17, non publién.p.16-17FY2017-18, <0,1 millions de dollars US<0,117-18FY2018-19, <0,1 millions de dollars US<0,118-19FY2019-20, <0,1 millions de dollars US<0,119-20FY2020-21, <0,1 millions de dollars US<0,120-21

Tableau 2.Nouveaux engagements et décaissements par exercice (flux), millions de dollars US

FY2016-17Millions de dollars USFY2017-18Millions de dollars USFY2018-19Millions de dollars USFY2019-20Millions de dollars USFY2020-21Millions de dollars US
Nouveaux engagements<0,1Non publiéNon publiéNon publiéNon publié
DécaissementsNon publié<0,1<0,1<0,1<0,1
Décaissements cumulésNon publié<0,1<0,1<0,1<0,1

Fiches et documents

Écritures15 écritures, du 1er juillet 2017 au 31 mars 2021

Tableau 3.Écritures, millions de dollars US

DateMesureMontantMillions de dollars USSourceMéthode
1er juillet 2017Engagement<0,1IATIIATI commitment (transaction type 2); converted: GBP at 2017 annual average (Federal Reserve G.5A/G.5 via FRED)
31 décembre 2017Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 mars 2018Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
30 juin 2018Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
30 septembre 2018Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 décembre 2018Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 mars 2019Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
30 juin 2019Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
30 septembre 2019Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 décembre 2019Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 mars 2020Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
30 juin 2020Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
30 septembre 2020Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 décembre 2020Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
31 mars 2021Décaissements<0,1IATIIATI disbursement (transaction type 3), paid to another organization
Conditions5 des 6 publiés
Type de financement
110 Don standard
Type de flux
10 Aide publique au développement
Type d’aide
D02 Autres formes d’assistance technique
Aide liée ou non liée
5 Non lié
Type de collaboration
1 Bilatéral
Humanitaire
Non publié
Marqueurs de politique8 marqueurs de politique
Marqueur de politiqueImportanceSource
Égalité femmes-hommesNon cibléIATI
Réduction des risques de catastropheNon cibléIATI
HandicapNon cibléIATI
NutritionNon cibléIATI
BiodiversitéNon cibléIATI
Atténuation du changement climatiqueNon cibléIATI
Adaptation au changement climatiqueNon cibléIATI
DésertificationNon cibléIATI
Identifiants1 identifiant
SystèmeIdentifiantSource
Identifiant IATIGB-GOV-13-FUND--GCRF-MR_P022081_1IATI
Écarts entre les sources1 champ
ChampSourceValeurRetenue
EngagementIATI<0,1 millions de dollars US✓
EngagementIATI, activité entière (tous les pays)0,6 millions de dollars US

Documents du partenaire

Aucun document n’est listé pour cette opération.

Sources

Données au 18 octobre 2026
SourceLu le
Taux de change (Réserve fédérale, FMI)18 octobre 2026
IATI18 octobre 2026
Citer cette page

HaitiDocs. Cadre de modélisation mathématique pour l’estimation de la charge de la tuberculose. Portefeuille des partenaires, données au 18 octobre 2026. https://www.haitidocs.org/portfolio/projects/IATI%3AGB-GOV-13-FUND--GCRF-MR_P022081_1?lang=fr